{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T04:28:38Z","timestamp":1717302518272},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T00:00:00Z","timestamp":1126569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Paracetamol\u2010containing combination analgesics are widely prescribed but the use of paracetamol\/dextropropoxyphene (co\u2010proxamol) is particularly controversial. We aim to examine the prescribing patterns of the paracetamol\u2010containing analgesics in Ireland.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A national primary care prescribing database was used to investigate patterns of usage. Twenty\u2010six thousand three hundred and eighteen patients who were new to therapy with paracetamol and paracetamol\u2010containing analgesics between January and June 2002 were identified as follows: no previous analgesic medication in the 6\u2003months prior to enrolment into the study, and followed up for at least 12\u2003months from the time of enrolment. Duration of therapy and the number of prescriptions received post enrolment were analyzed according to age. Odds ratios for receiving long\u2010term (&gt;1\u2003month) compared with short\u2010term (1\u2003month) prescriptions for co\u2010proxamol, paracetamol only or a paracetamol combination\u2010type analgesic were calculated for women <jats:italic>vs.<\/jats:italic> men, and in those aged over 65 <jats:italic>vs.<\/jats:italic> those aged under 65\u2003years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Co\u2010proxamol was the most commonly prescribed analgesic, accounting for 42% of all prescriptions dispensed during 2003. Long\u2010term use of paracetamol\u2010containing analgesic preparations was uncommon, with 56.7% receiving only 1\u2003month's prescription during the study period. However, women (OR\u2003=\u20031.18, 95% CI 1.07, 1.28, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001) and those over 65\u2003years (OR\u2003=\u20031.71, 95% CI 1.57, 1.86, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.0001) were more likely to receive a follow\u2010up prescription for co\u2010proxamol, but also for paracetamol (women, OR\u2003=\u20031.28, 95% CI 1.16, 1.39; over 65\u2003year olds, OR\u2003=\u20032.67, 95%CI 2.44, 2.93) and the paracetamol combinations (women, OR\u2003=\u20031.33, 95% CI 1.20, 1.47; over 65\u2003year olds, OR\u2003=\u20031.69, 95% CI 1.53, 1.87).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Co\u2010proxamol was the most commonly prescribed paracetamol\u2010containing analgesic preparation in Ireland. The results may indicate inappropriate use in primary care.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2005.02500.x","type":"journal-article","created":{"date-parts":[[2005,9,13]],"date-time":"2005-09-13T11:41:44Z","timestamp":1126611704000},"page":"648-652","source":"Crossref","is-referenced-by-count":6,"title":["Usage of paracetamol\u2010containing combination analgesics remains high in primary care"],"prefix":"10.1111","volume":"60","author":[{"given":"Cara","family":"Usher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Teeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernie","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Feely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,9,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91665-7"},{"key":"e_1_2_6_3_2","first-page":"77","article-title":"Co\u2010proxamol or paracetamol for acute pain?","volume":"36","author":"Anonymous.","year":"1998","journal-title":"Drugs and Therapeutics Bulletin"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7122.1565"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7149.1980"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1742-1241.1995.tb09973.x","article-title":"Compound opioid\/paracetamol analgesics: misuse and dependence","volume":"49","author":"McBride A.","year":"1995","journal-title":"Br J Clin Pract"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.22.2716"},{"key":"e_1_2_6_8_2","unstructured":"LawrenceA.Letter to Interested organisations and individuals: Review of the utility of the pain reliever co\u2010proxamol (Co\u2010proxamol; cosalgesic; dolgesic) and request for evidence on risks and benefits. MHRA30th June 2004:http:\/\/www.mhra.gov.uk."},{"key":"e_1_2_6_9_2","unstructured":"Anonymous.Co\u2010proxamol to be withdrawn from the market. MHRA31st January 2005http:\/\/www.mhra.gov.uk."},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","unstructured":"WilliamsD BennettK FeelyJ.The application of prescribing indicators to a primary care prescription database in Ireland.Eur J Clin Pharmacol2005;(in press).","DOI":"10.1007\/s00228-004-0876-3"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7409.287-a"},{"key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/dtb.21.5.17","article-title":"Distalgesic and it equivalents. Time for action","volume":"21","author":"Anonymous.","year":"1983","journal-title":"Drug and Therapeutics Bulletin"},{"key":"e_1_2_6_13_2","first-page":"81","article-title":"Drugs that cause psychiatric symptoms","volume":"28","author":"Anonymous.","year":"1986","journal-title":"The Med Letter"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/096032718400300116"},{"key":"e_1_2_6_15_2","unstructured":"CourtneyP DohertyM.Current drug treatment of osteoarthritis in primary care.Prescriber19 February 2004 52\u201360."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01795.x"},{"key":"e_1_2_6_17_2","first-page":"103","article-title":"Development and validation of an improving prescribing in the elderly tool","volume":"7","author":"Naugler CT","year":"2000","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_2_6_18_2","unstructured":"EdwardsIRDextropropoxyphene.NZ Med J1985 27th March 201."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1989.tb03527.x"},{"key":"e_1_2_6_20_2","first-page":"S2205","article-title":"The management of persistent pain in older persons","volume":"50","author":"American Geriatric Society Panel on Persistent Pain in Older Persons.","year":"2002","journal-title":"J Am Geriat Soc"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1331\/108658002762063682"},{"key":"e_1_2_6_22_2","first-page":"64","article-title":"The opioid analgesics: rational selection of agents for acute and chronic pain","volume":"22","author":"Hare B","year":"1987","journal-title":"Hospital Formulary"},{"key":"e_1_2_6_23_2","unstructured":"Committee on Safety of Medicines.Risk: benefit of co\u2010proxamol. Current problems in pharmacovigilance 30. London:Committee on Safety of Medicines 2004."},{"key":"e_1_2_6_24_2","volume-title":"Therapeutic drugs","author":"Dollery C.","year":"1999"},{"key":"e_1_2_6_25_2","first-page":"562","volume-title":"Pharmacology","author":"Rang HP","year":"2003"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7409.287-b"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7397.1006"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7409.287"},{"key":"e_1_2_6_29_2","unstructured":"Anonymous.Irish Medicines Board.Statement \u2013 Dextropropoxyphene\/Paracetamol1st February 2005:http:\/\/www.imb.ie."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2005.02500.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2005.02500.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:57:11Z","timestamp":1697439431000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2005.02500.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,13]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1365-2125.2005.02500.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02500.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9,13]]}}}